TNF-mediated inflammatory disease

Journal of Pathology

Volumn 214, Issue 2, 2008, Pages 149-160

  Bradley, J R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Arthritis; Infection; Inflammation; Signal transduction; Therapy; Tumour necrosis factor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANKYLOSING SPONDYLITIS; ASTHMA; CARDIOVASCULAR DISEASE; CELL DEATH; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG POTENTIATION; ENDOTHELIUM CELL; ENTERITIS; HUMAN; INFLAMMATION; KIDNEY DISEASE; LEUKOCYTE ADHERENCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PSORIASIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; THROMBOSIS; ULCERATIVE COLITIS; WEGENER GRANULOMATOSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; COMMUNICABLE DISEASES; HUMANS; INFLAMMATION; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38549102077     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2287     Document Type: Review

References (148)

1. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72(9):3666-3670.
2. Pennica D, Hayflick JS, Bringman TS, Palladino MA, Goeddei DV. Cloning and expression in Escherichia coli of the cDNA for murine tumor necrosis factor. Proc Natl Acad Sci USA 1985;82(18):6060-6064.
3. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, et al. A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 1997;385(6618):729-733.
4. Wang J, Al-Lamki RS, Zhang H, Kirkiles-Smith N, Gaeta ML, Thiru S, et al. Histamine antagonizes tumor necrosis factor (TNF) signalling by stimulating TNF receptor shedding from the cell surface and Golgi storage pool. J Biol Chem 2003;278(24):21751-21760.
5. Robak T, Gladalska A, Stepien H. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis. Eur Cytokine Netw 1998;9(2):145-154.
6. Nurnberger W, Platonov A, Stannigel H, Beloborodov VB, Michelmann I, von Kries R, et al. Definition of a new score for severity of generalized Neisseria meningitidis infection. Eur J Pediatr 1995;154(11):896-900.
7. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1(8529):355-357.
8. Kwiatkowski D, Hill AV, Sambou I, Twumasi P, Castracane J, Manogue KR, et al. TNF concentration in fatal cerebral, non-fatal cerebral, and uncomplicated Plasmodium falciparum malaria. Lancet 1990;336(8725):1201-1204.
9. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, et al. A physical and functional map of the human TNFα/NF-κB signal transduction pathway. Nat Cell Biol 2004;6(2):97-105.
10. Al-Lamki RS, Wang J, Skepper JN, Thiru S, Pober JS, Bradley JR. Expression of tumor necrosis factor receptors in normal kidney and rejecting renal transplants. Lab Invest 2001;81(11):1503-1515.
11. Ledgerwood EC, Pober JS, Bradley JR. Recent advances in the molecular basis of TNF signal transduction. Lab Invest 1999;79(9):1041-1050.
12. Jones SJ, Ledgerwood EC, Prins JB, Galbraith J, Johnson DR, Pober JS, et al. TNF recruits TRADD to the plasma membrane but not the trans-Golgi network, the principal subcellular location of TNF-R1. J Immunol 1999;162(2):1042-1048.
13. Bennett M, Macdonald K, Chan SW, Luzio JP, Simari R. Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998;282(5387):290-293.
14. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL. Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signalling. Science 2000;288(5475):2351-2354.
15. Jiang Y, Woronicz JD, Liu W, Goeddel DV. Prevention of constitutive TNF receptor 1 signalling by silencer of death domains. Science 1999;283:543-546.
16. Endres R, Hacker G, Brosch I, Pfeffer K. Apparently normal tumor necrosis factor receptor 1 signalling in the absence of the silencer of death domains. Mol Cell Biol 2003;23(18):6609-6617.
17. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signalling complex. Immunity 1996;4:387-396.
18. Takeuchi M, Rothe M, Goeddel DV. Anatomy of TRAF2. Distinct domains for nuclear factor-κB activation and association with tumor necrosis factor signalling proteins. J Biol Chem 1996;271:19935-19942.
19. Bradley JR, Johnson DR, Pober JS. Four different classes of inhibitors of receptor-mediated endocytosis decrease TNF-induced gene expression in human endothelial cells. J Immunol 1993;150:5544-5555.
20. Schutze S, Machleidt T, Adam D, Schwandner R, Wiegmann K, Kruse ML, et al. Inhibition of receptor internalization by monodansylcadaverine selectively blocks p55 tumor necrosis factor receptor death domain signalling. J Biol Chem 1999;274:10203-10212.
21. Yang J, Lin Y, Guo Z, Cheng J, Huang J, Deng L, et al. The essential role of MEKK3 in TNF-induced NF-κB activation. Nat Immunol 2001;2:620-624.
22. Blonska M, Shambharkar PB, Kobayashi M, Zhang D, Sakurai H, Su B, et al. TAK1 is recruited to the tumor necrosis factor-alpha (TNFα) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3, leading to NF-κB activation. J Biol Chem 2005;280:43056-43063.
23. Devin A, Lin Y, Yamaoka S, Li Z, Karin M, Liu Z. The α- and β-subunits of IκB kinase (IKK) mediate TRAF2-dependent IKK recruitment to tumor necrosis factor (TNF) receptor 1 in response to TNF. Mol Cell Biol 2001;21:3986-3994.
24. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol 2005;7:758-765.
25. Nishitoh H, Saitoh M, Mochida Y, Takeda K, Nakano H, Rothe M, et al. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 1998;2(3):389-395.
26. Ichijo H, Nishida E, Irie K, ten Dijke P, Saitoh M, Moriguchi T, et al. Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signalling pathways. Science 1997;275:90-94.
27. Nishitoh H, Saitoh M, Mochida Y, Takeda K, Nakano H, Rothe M, et al. ASK1 is essential for JNK/SAPK activation by TRAF2. Mol Cell 1998;2:389-395.
28. Adam-Klages S, Adam D, Wiegmann K, Struve S, Kolanus W, Schneider-Mergener J, et al. FAN, a novel WD-repeat protein, couples the p55 TNF-receptor to neutral sphingomyelinase. Cell 1996;86:937- 947.
29. Slowik MR, De Luca LG, Min W, Pober JS. Ceramide is not a signal for tumor necrosis factor-induced gene expression but does cause programmed cell death in human vascular endothelial cells. Circ Res 1996;79:736- 747.
30. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-κB signals induce the expression of c-FLIP. Mol Cell Biol 2001;21:5299-5305.
31. Xu XS, Vanderziel C, Bennett CF, Monia BP. A role for c-Raf kinase and Ha-Ras in cytokine-mediated induction of cell adhesion molecules. J Biol Chem 1998;273:33230-343238.
32. Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, et al. SIN1/MIP1 Maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006;127:125-137.
33. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 1997;9:180-186.
34. Rothe M, Wong SC, Henzel WJ, Goeddel DV. A novel family of putative signal transducers associated with the cytoplasmic domain of the 75 kDa tumor necrosis factor receptor. Cell 1994;78(4):681-692.
35. Grech AP, Gardam S, Chan T, Quinn R, Gonzales R, Basten A, et al. Tumor necrosis factor receptor 2 (TNFR2) signalling is negatively regulated by a novel, carboxyl-terminal TNFR-associated factor 2 (TRAF2)-binding site. J Biol Chem 2005;280(36):31572-31581.
36. Zhao Y, Conze DB, Hanover JA, Ashwell JD. Tumor necrosis factor receptor 2 signalling induces selective c-IAP1-dependent ASK1 ubiquitination and terminates mitogen-activated protein kinase signalling. J Biol Chem 2007;282(11):7777-7782.
37. Zhang R, Xu Y, Ekman N, Wu Z, Wu J, Alitalo K, et al. Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. J Biol Chem 2003;278(51):51267-51276.
38. Al-Lamki RS, Wang J, Vandenabeele P, Bradley JA, Thiru S, Luo D, et al. TNFR1- and TNFR2-mediated signalling pathways in human kidney are cell type-specific and differentially contribute to renal injury. FASEB J 2005;19(12):1637-1645.
39. Slowik MR, De Luca LG, Fiers W, Pober JS. Tumor necrosis factor activates human endothelial cells through the p55 tumor necrosis factor receptor but the p75 receptor contributes to activation at low tumor necrosis factor concentration. Am J Pathol 1993;143(6):1724-1730.
40. Tartaglia LA, Pennica D, Goeddel DV. Ligand passing: the 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signalling by the 55-kDa TNF receptor. J Biol Chem 1993;268(25):18542-18548.
41. Pinckard JK, Sheehan KC, Schreiber RD. Ligand-induced formation of p55 and p75 tumor necrosis factor receptor heterocomplexes on intact cells. J Biol Chem 1997;272(16):10784-10789.
42. Santee SM, Owen-Schaub LB. Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization. J Biol Chem 1996;271(35):21151-21159.
43. Kalthoff H, Roeder C, Brockhaus M, Thiele HG, Schmiegel W. Tumor necrosis factor (TNF) up-regulates the expression of p75 but not p55 TNF receptors, and both receptors mediate, independently of each other, up-regulation of transforming growth factor alpha and epidermal growth factor receptor mRNA. J Biol Chem 1993;268(4):2762-2766.
44. Winzen R, Wallach D, Engelmann H, Nophar Y, Brakebusch C, Kemper O, et al. Selective decrease in cell surface expression and mRNA level of the 55-kDa tumor necrosis factor receptor during differentiation of HL-60 cells into macrophage-like but not granulocyte-like cells. J Immunol 1992;148(11):3454-3460.
45. Winzen R, Wallach D, Kemper O, Resch K, Holtmann H. Selective up-regulation of the 75-kDa tumor necrosis factor (TNF) receptor and its mRNA by TNF and IL-1. J Immunol 1993;150(10):4346-4353.
46. Kemper O, Wallach D. Cloning and partial characterization of the promoter for the human p55 tumor necrosis factor (TNF) receptor. Gene 1993;134(2):209-216.
47. Rothe J, Bluethmann H, Gentz R, Lesslauer W, Steinmetz M. Genomic organization and promoter function of the murine tumor necrosis factor receptor beta gene. Mol Immunol 1993;30(2):165-175.
48. Nophar Y, Kemper O, Brakebusch C, Englemann H, Zwang R, Aderka D, et al. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor. EMBO J 1990;9(10):3269-3278.
49. Madge LA, Sierra-Honigmann MR, Pober JS. Apoptosis-inducing agents cause rapid shedding of tumor necrosis factor receptor 1 (TNFR1). A nonpharmacological explanation for inhibition of TNF-mediated activation. J Biol Chem 1999;274(19):13643-13649.
50. Bradley JR, Johnson DR, Pober JS. Endothelial activation by hydrogen peroxide. Selective increases of intercellular adhesion molecule-1 and major histocompatibility complex class I. Am J Pathol 1993;142(5):1598- 1609.
51. Hino T, Nakamura H, Abe S, Saito H, Inage M, Terashita K, et al. Hydrogen peroxide enhances shedding of type I soluble tumor necrosis factor receptor from pulmonary epithelial cells. Am J Resp Cell Mol Biol 1999;20(1):122-128.
52. McDermott MF, Aksentijevich I, Galon J, McDermott EM, Ogunkolade BW, Centola M, et al. Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell 1999;97(1):133-144.
53. Lobito AA, Kimberley FC, Muppidi JR, Komarow H, Jackson AJ, Hull KM, et al. Abnormal disulfide-linked oligomerization results in ER retention and altered signalling by TNFR1 mutants in TNFR1-associated periodic fever syndrome (TRAPS). Blood 2006;108(4):1320-1327.
54. Messadi DV, Pober JS, Fiers W, Gimbrone MA Jr, Murphy GF. Induction of an activation antigen on postcapillary venular endothelium in human skin organ culture. J Immunol 1987;139:1557-1562.
55. Petzelbauer P, Pober JS, Keh A, Braverman IM. Inducibility and expression of microvascular endothelial adhesion molecules in lesional, perilesional, and uninvolved skin of psoriatic patients. J Invest Dermatol 1994;103:300-305.
56. Bradley JR, Pober JS. Prolonged cytokine exposure causes a dynamic redistribution of endothelial cell adhesion molecules to intercellular junctions. Lab Invest 1996;75(4):463-472.
57. Pober JS, Bevilacqua MP, Mendrick DL, Lapierre LA, Fiers W, Gimbrone MA Jr. Two distinct monokines, interleukin 1 and tumor necrosis factor, each independently induce biosynthesis and transient expression of the same antigen on the surface of cultured human vascular endothelial cells. J Immunol 1986;136:1680-1687.
58. Munro JM, Pober JS, Cotran RS. Tumor necrosis factor and interferon-g induce distinct patterns of endothelial activation and associated leukocyte accumulation in skin of Papio anubis. Am J Pathol 1989;135:121- 133.
59. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol 1990;136:1229-1233.
60. Mark KS, Trickler WJ, Miller DW. Tumor necrosis factor-alpha induces cyclooxygenase-2 expression and prostaglandin release in brain microvessel endothelial cells. J Pharmacol Exp Therap 2001;297(3):1051-1058.
61. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc Natl Acad Sci USA 1986;83(12):4533-4537.
62. Cerami A, Ikeda Y, Le Trang N, Hotez PJ, Beutler B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett 1985;11(3-4):173-177.
63. Beutler BA, Milsark IW, Cerami A. Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo. J Immunol 1985;135(6):3972-3977.
64. Tracey KJ, Fong Y, Hesse DG, Manogue KR, Lee AT. Kuo GC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987;330(6149):662-664.
65. Fisher CJ Jr, Agosti JM, Opal SM, Lowry SF, Balk RA, Sadoff JC, et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996;334(26):1697-1702.
66. Pfeffer K, Matsuyama T, Kundig TM, Wakeham A, Kishihara K, Shahinian A, et al. Mice deficient for the 55 kDa tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 1993;73(3):457-467.
67. Rothe J, Lesslauer W, Lotscher H, Lang Y, Koebel P, Kontgen F, et al. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993;364(6440):798-802.
68. Peschon JJ, Torrance DS, Stocking KL, Glaccum MB, Otten C, Willis CR, et al. TNF receptor-deficient mice reveal divergent roles for p55 and p75 in several models of inflammation. J Immunol 1998;160(2):943-952.
69. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168(9):4620-4627.
70. Wallis RS, Broder M, Wong J, Lee A, Hoq L. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005;41(suppl 3):S194-198.
71. Rudin W, Eugster HP, Bordmann G, Bonato J, Muller M, Yamage M, et al. Resistance to cerebral malaria in tumor necrosis factor-alpha/beta- deficient mice is associated with a reduction of intercellular adhesion molecule-1 up-regulation and T helper type 1 response. Am J Pathol 1997;150(1):257-266.
72. Kwiatkowski D, Molyneux ME, Stephens S, Curtis N, Klein N, Pointaire P, et al. Anti-TNF therapy inhibits fever in cerebral malaria. Qu J Med 1993;86(2):91-98.
73. van Hensbroek MB, Palmer A, Onyiorah E, Schneider G, Jaffar S, Dolan G, et al. The effect of a monoclonal antibody to tumor necrosis factor on survival from childhood cerebral malaria. J Infect Dis 1996;174(5):1091-1097.
74. Smith CA, Davis T, Anderson D, Solam L, Beckmann MP, Jerzy R, et al. A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 1990;248(4958):1019-1023.
75. Creagan ET, Kovach JS, Moertel CG, Frytak S, Kvols LK. A phase I clinical trial of recombinant human tumor necrosis factor. Cancer 1988;62(12):2467-2471.
76. Feinberg B, Kurzrock R, Talpaz M, Blick M, Saks S, Gutterman JU. A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. J Clin Oncol 1988;6(8):1328-1334.
77. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999;5(7):828-831.
78. Grunhagen DJ, de Wilt JH, Graveland WJ, van Geel AN, Eggermont AM. The palliative value of tumor necrosis factor alpha-based isolated limb perfusion in patients with metastatic sarcoma and melanoma. Cancer 2006;106(1):156-162.
79. Grunhagen DJ, van Etten B, Brunstein F, Graveland WJ, van Geel AN, de Wilt JH, et al. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure. Ann Surg Oncol 2005;12(8):609-615.
80. van Etten B, de Vries MR, van IMG, Lans TE, Guetens G, Ambagtsheer G, et al. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNFα-based isolated hepatic perfusion. Br J Cancer 2003;88(2):314-319.
81. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Therap 2002;301(2):418-426.
82. Grell M, Douni E, Wajant H, Lohden M, Clauss M, Maxeiner B, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell 1995;83(5):793- 802.
83. Koch AE, Harlow LA, Haines GK, Amento EP, Unemori EN, Wong WL, et al. Vascular endothelial growth factor. A cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994;152(8):4149-4156.
84. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996;14:397-440.
85. Brennan FM, Chantry D, Jackson A, Maini R, Feldmann M. Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989;2(8657):244-247.
86. Butler DM, Maini RN, Feldmann M, Brennan FM. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNFα antibody with the interleukin-1 receptor antagonist. Eur Cytokine Netw 1995;6(4):225-230.
87. Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 1992;89(20):9784-9788.
88. Thorbecke GJ, Shah R, Leu CH, Kuruvilla AP, Hardison AM, Palladino MA. Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice. Proc Natl Acad Sci USA 1992;89(16):7375-7379.
89. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992;77(4):510-514.
90. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies Immunity 1999;10(3):387-398.
91. Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthrit Rheumat 1993;36(12):1681-1690.
92. Elliott MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994;344(8930):1105-1110.
93. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthrit Rheumat 1998;41(9):1552-1563.
94. Moreland LW. Clinical and pharmacological experience with etanercept. Exp Opin Invest Drugs 1999;8(9):1443-1451.
95. Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343(22):1594- 1602.
96. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheumat Dis 2004;63(5):508-516.
97. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthrit Rheumat 2004;50(5):1400-1411.
98. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363(9410):675-681.
99. Buch MH, Bingham SJ, Bryer D, Emery P. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. Rheumatology 2007;46(7):1153-1156.
100. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106(6):1455-1466.
101. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993;34(12):1705-1709.
102. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet 2002;359(9317):1541-1549.
103. Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004;350(9):876-885.
104. Sandborn WJ, Feagan BG, Hanauer SB, Present DH, Sutherland LR, Kamm MA, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001;120(6):1330-1338.
105. Sandborn WJ, Feagan BG, Radford-Smith G, Kovacs A, Enns R, Innes A, et al. CDP571, a humanized monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomized, double blind, placebo controlled trial. Gut 2004;53(10):1485-1493.
106. Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst Rev http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD003574/frame. html.
107. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Reviews http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/ CD005112/frame.html.
108. Braun J, Bollow M, Neure L, Seipelt E, Seyrekbasan F, Herbst H, et al. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthrit Rheumat 1995;38(4):499-505.
109. Francois RJ, Neure L, Sieper J, Braun J. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. Ann Rheumat Dis 2006;65(6):713-720.
110. Lange U, Teichmann J, Stracke H. Correlation between plasma TNFα, IGF-1, biochemical markers of bone metabolism, markers of inflammation/disease activity, and clinical manifestations in ankylosing spondylitis. Eur J Med Res 2000;5(12):507-511.
111. Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346(18):1349-1356.
112. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheumat Dis 2005;64(10):1462-1466.
113. Davis JC, van der Heijde DM, Braun J, Dougados M, Cush J, Clegg D, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheumat Dis 2005;64(11):1557-1562.
114. Inman RD, Clegg DO, Davis JC, Whitmore JB, Solinger A. Etanercept in adult patients with early onset ankylosing spondylitis. J Rheumatol 2006;33(8):1634-1636.
115. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002;359(9313):1187-1193.
116. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, et al. Safety and efficacy of readministration of infliximab after long-term continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007;34(3):510-515.
117. Kristensen M, Chu CQ, Eedy DJ, Feldmann M, Brennan FM, Breathnach SM. Localization of tumour necrosis factor-alpha (TNFα) and its receptors in normal and psoriatic skin: epidermal cells express the 55 kDa but not the 75 kDa TNF receptor. Clin Exp Immunol 1993;94(2):354-362.
118. Ettehadi P, Greaves MW, Wallach D, Aderka D, Camp RD. Elevated tumour necrosis factor-alpha (TNFα) biological activity in psoriatic skin lesions. Clin Exp Immunol 1994;96(1):146-151.
119. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial. Lancet 2001;357(9271):1842-1847.
120. Gottlieb AB, Evans R, Li S, Dooley LT, Guzzo CA, Baker D, et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004;51(4):534-542.
121. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349(21):2014-2022.
122. Antoni CE, Kavanaugh A, Kirkham B, Tutuncu Z, Burmester GR, Schneider U, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthrit Rheumat 2005;52(4):1227-1236.
123. Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34(5):1040-1050.
124. Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, et al. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol 2007;143(6):719-726.
125. Feuerstein GZ, Liu T, Barone FC. Cytokines, inflammation, and brain injury: role of tumor necrosis factor-alpha. Cerebrovasc Brain Metab Rev 1994;6(4):341-360.
126. Shohami E, Ginis I, Hallenbeck JM. Dual role of tumor necrosis factor alpha in brain injury. Cytokine Growth Factor Rev 1999;10(2):119- 130.
127. Nawashiro H, Martin D, Hallenbeck JM. Neuroprotective effects of TNF binding protein in focal cerebral ischemia. Brain Res 1997;778(2):265-271.
128. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, et al. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 1998;4(1):78-83.
129. Kassiotis G, Kollias G. Uncoupling the proinflammatory from the immunosuppressive properties of tumor necrosis factor (TNF) at the p55 TNF receptor level: implications for pathogenesis and therapy of autoimmune demyelination. J Exp Med 2001;193(4):427-434.
130. Arnett HA, Mason J, Marino M, Suzuki K, Matsushima GK, Ting JP. TNFα promotes proliferation of oligodendrocyte progenitors and remyelination. Nat Neurosci 2001;4(11):1116-1122.
131. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1999;53(3):457-465.
132. Higuchi Y, McTiernan CF, Frye CB, McGowan BS, Chan TO, Feldman AM. Tumor necrosis factor receptors 1 and 2 differentially regulate survival, cardiac dysfunction, and remodeling in transgenic mice with tumor necrosis factor-alpha-induced cardiomyopathy. Circulation 2004;109(15): 1892-1897.
133. Suzuki J, Cole SE, Batirel S, Kosuge H, Shimizu K, Isobe M, et al. Tumor necrosis factor receptor-1 and -2 double deficiency reduces graft arterial disease in murine cardiac allografts. Am J Transpl 2003;3(8):968-976.
134. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am J Med 2004;116(5):305-311.
135. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNFα in pulmonary pathophysiology. Resp Res 2006;7:125.
136. Cembrzynska-Nowak M, Szklarz E, Inglot AD, Teodorczyk-Injeyan JA. Elevated release of tumor necrosis factor-alpha and interferon-gamma by bronchoalveolar leukocytes from patients with bronchial asthma. Am Rev Resp Dis 1993;147(2):291-295.
137. Howarth PH, Babu KS, Arshad HS, Lau L, Buckley M, McConnell W, et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax 2005;60(12): 1012-1018.
138. Berry MA, Hargadon B, Shelley M, Parker D, Shaw DE, Green RH, et al. Evidence of a role of tumor necrosis factor alpha in refractory asthma. N Engl J Med 2006;354(7):697-708.
139. Vielhauer V, Stavrakis G, Mayadas TN. Renal cell-expressed TNF receptor 2, not receptor 1, is essential for the development of glomerulonephritis. J Clin Invest 2005;115(5):1199-1209.
140. Lamprecht P, Voswinkel J, Lilienthal T, Nolle B, Heller M, Gross WL, et al. Effectiveness of TNFα blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology 2002;41(11):1303-1307.
141. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005;352(4):351-361.
142. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. Biologics for the treatment of juvenile idiopathic arthritis: a systematic review and critical analysis of the evidence. Clin Rheumatol 2008;27:67-76.
143. Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003;30(8):1864-1867.
144. Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE. Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthrit Rheumat 2003;48(12):3542-3543.
145. Baughman RP, Drent M, Kavuru M, Judson MA, Costabel U, du Bois R, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Resp Crit Care Med 2006;174(7):795-802.
146. Efthimiou P. Tumor necrosis factor-alpha in inflammatory myopathies: pathophysiology and therapeutic implications. Semin Arthrit Rheumat 2006;36(3):168-172.
147. Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNFα blockade in cyclophosphamide-resistant neuro-Behcet disease. J Neurol Neurosurg Psychiat 2005;76(12):1733-1735.
148. Sobrin L, Kim EC, Christen W, Papadaki T, Letko E, Foster CS. Infliximab therapy for the treatment of refractory ocular inflammatory disease. Arch Ophthalmol 2007;125(7):895-900.